A Study of Fabrazyme in Pediatric Patients With Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

May 31, 2005

Study Completion Date

July 31, 2005

Conditions
Fabry Disease
Interventions
BIOLOGICAL

Fabrazyme (agalsidase beta)

1 mg/kg every 2 weeks

Trial Locations (7)

85724

University of Arizona, Tucson

Cedex 03

Hopital Edouard Herriot, Lyon

Cedex 05

Hopital de la Timone Enfants, Marseille

Cedex 15

Hopital Europeen Georges Pompidou, Paris

04-730

Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw

M27 4HA

Royal Manchester Children's Hospital, Pendlebury

WC1N 3JH

Great Ormond Street Hospital for Sick Children, London

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00074958 - A Study of Fabrazyme in Pediatric Patients With Fabry Disease | Biotech Hunter | Biotech Hunter